Literature DB >> 18698023

Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.

Mona Shehata1, Ivan Bièche, Rose Boutros, Judith Weidenhofer, Susan Fanayan, Lisa Spalding, Nikolajs Zeps, Karen Byth, Robert K Bright, Rosette Lidereau, Jennifer A Byrne.   

Abstract

PURPOSE: Tumor protein D52 (TPD52 or D52) is frequently overexpressed in breast and other cancers and present at increased gene copy number. It is, however, unclear whether D52 amplification and overexpression target specific functional properties of the encoded protein. EXPERIMENTAL
DESIGN: The expression of D52-like genes and MAL2 was compared in breast tissues using quantitative reverse transcription-PCR. The functions of human D52 and D53 genes were then compared by stable expression in BALB/c 3T3 fibroblasts and transient gene knockdown in breast carcinoma cell lines. In situ D52 and MAL2 protein expression was analyzed in breast tissue samples using tissue microarray sections.
RESULTS: The D52 (8q21.13), D54 (20q13.33), and MAL2 (8q24.12) genes were significantly overexpressed in breast cancer tissue (n = 95) relative to normal breast (n = 7; P </= 0.005) unlike the D53 gene (6q22.31; P = 0.884). Subsequently, D52-expressing but not D53-expressing 3T3 cell lines showed increased proliferation and anchorage-independent growth capacity, and reduced D52 but not D53 expression in SK-BR-3 cells significantly increased apoptosis. High D52 but not MAL2 expression was significantly associated with reduced overall survival in breast carcinoma patients (log-rank test, P < 0.001; n = 357) and was an independent predictor of survival (hazard ratio, 2.274; 95% confidence interval, 1.228-4.210; P = 0.009; n = 328).
CONCLUSION: D52 overexpression in cancer reflects specific targeting and may contribute to a more proliferative, aggressive tumor phenotype in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698023     DOI: 10.1158/1078-0432.CCR-07-4994

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  TPD52 expression increases neutral lipid storage within cultured cells.

Authors:  Alvin Kamili; Nuruliza Roslan; Sarah Frost; Laurence C Cantrill; Dongwei Wang; Austin Della-Franca; Robert K Bright; Guy E Groblewski; Beate K Straub; Andrew J Hoy; Yuyan Chen; Jennifer A Byrne
Journal:  J Cell Sci       Date:  2015-07-16       Impact factor: 5.285

2.  Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting.

Authors:  Christoph Biesemann; Mads Grønborg; Elisa Luquet; Sven P Wichert; Véronique Bernard; Simon R Bungers; Ben Cooper; Frédérique Varoqueaux; Liyi Li; Jennifer A Byrne; Henning Urlaub; Olaf Jahn; Nils Brose; Etienne Herzog
Journal:  EMBO J       Date:  2014-01-10       Impact factor: 11.598

3.  Role of annexin A6 in cancer.

Authors:  Houbao Qi; Shuqing Liu; Chunmei Guo; Jiasheng Wang; Frederick T Greenaway; Ming-Zhong Sun
Journal:  Oncol Lett       Date:  2015-07-15       Impact factor: 2.967

Review 4.  Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Authors:  Jennifer A Byrne; Sarah Frost; Yuyan Chen; Robert K Bright
Journal:  Tumour Biol       Date:  2014-05-06

5.  A role for tumor protein TPD52 phosphorylation in endo-membrane trafficking during cytokinesis.

Authors:  Diana D H Thomas; Christina L Frey; Scott W Messenger; Benjamin K August; Guy E Groblewski
Journal:  Biochem Biophys Res Commun       Date:  2010-10-12       Impact factor: 3.575

6.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

7.  Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Authors:  Teresa Cabezón; Irina Gromova; Pavel Gromov; Reza Serizawa; Vera Timmermans Wielenga; Niels Kroman; Julio E Celis; José M A Moreira
Journal:  Mol Cell Proteomics       Date:  2012-11-20       Impact factor: 5.911

8.  Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.

Authors:  Guodong Li; Lei Yao; Jinning Zhang; Xinglong Li; Shuwei Dang; Kai Zeng; Yuhui Zhou; Feng Gao
Journal:  Tumour Biol       Date:  2015-12-17

9.  Tumor protein D52 represents a negative regulator of ATM protein levels.

Authors:  Yuyan Chen; Alvin Kamili; Jayne R Hardy; Guy E Groblewski; Kum Kum Khanna; Jennifer A Byrne
Journal:  Cell Cycle       Date:  2013-08-21       Impact factor: 4.534

10.  Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.

Authors:  C Riccay Elizondo; Jennifer D Bright; Jennifer A Byrne; Robert K Bright
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.